干燥综合征患者发生重症新型冠状病毒肺炎的早期预测

doi:10.19723/j.issn.1671-167X.2023.06.008

摘要/Abstract

摘要：

目的: 探讨血细胞比值及炎症指标对干燥综合征(primary Sjögren’ s syndrome，PSS)合并新型冠状病毒肺炎(coronavirus disease 2019，COVID-19)预后不良的预测价值。方法: 选择2022年12月至2023年2月在南昌大学第一附属医院风湿免疫科就诊并具有所需完整临床资料的80例干燥综合征合并COVID-19患者进行回顾性分析，纳入标准: (1)符合2019年美国风湿病学会(American College of Rheumatology，ACR)干燥综合征诊断标准；(2)经实时逆转录聚合酶链式反应严重急性呼吸综合征冠状病毒2核酸检测或抗原检测确诊的COVID-19患者; (3)有所需完整临床资料；(4)年龄>18岁。依据《新型冠状病毒肺炎诊疗方案(试行第十版)》临床分型标准，将轻型、普通型患者合为轻症组，重型及危重型合为重症组。干燥综合征疾病活动判定方法参考欧洲抗风湿病联盟(European League Against Rheumatism，EULAR)制定的干燥综合征病情评估指数(EULAR Sjögren’ s syndrome disease activity index，ESSDAI)评分。比较两组患者感染后24~72 h内的血小板-淋巴细胞比值(platelet-lymphocyte ratio，PLR)和C反应蛋白-淋巴细胞比值(C-reactive protein-lymphocyte ratio，CLR)及红细胞沉降率(erythrocyte sedimentation rate，ESR)、C反应蛋白(C-reactive protein，CRP)等实验室资料。结果: 轻症组66例，平均年龄(51.52±13.16)岁；重症组14例，平均年龄(52.64±10.20)岁。重症组患者的疾病活动度、CRP、血小板、PLR和CLR明显高于轻症组(P＜0.05)。以轻、重症为因变量，分别以年龄、疾病活动度、CRP、血小板、PLR和CLR作为自变量进行单因素分析，提示疾病活动、CRP、PLR和CLR与COVID-19的严重程度相关(P＜0.05)。多因素二元Logisitic回归分析进一步证实PLR(OR=1.016，P＜0.05)、CLR(OR=1.504，P＜0.05)是COVID-19重症患者的独立危险因素。ROC曲线分析显示PLR和CLR的曲线下面积分别为0.708(95%CI: 0.588~0.828)和0.725(95%CI: 0.578~0.871)，敏感度分别为0.429和0.803，特异度分别为0.714和0.758，PLR和CLR的最佳分界值分别为166.214和0.870。结论: PLR和CLR，尤其是CLR，或许是预测干燥综合征患者COVID-19预后的简易而有效的指标。

关键词: 干燥综合征, 新型冠状病毒肺炎, 预后, 血小板-淋巴细胞比值, C反应蛋白-淋巴细胞比值

Abstract:

Objective: To investigate the predictive value of blood cell ratios and inflammatory markers for adverse prognosis in patients with primary Sjögren’s syndrome (PSS) combined with coronavirus disease 2019 (COVID-19). Methods: We retrospectively collected clinical data from 80 patients with PSS and COVID-19 who visited the Rheumatology and Immunology Department of the First Affiliated Hospital of Nanchang University from December 2022 to February 2023. Inclusion criteria were (1) meeting the American College of Rheumatology (ACR) classification criteria for Sjögren’s syndrome; (2) confirmed diagnosis of COVID-19 by real-time reverse transcription polymerase chain reaction or antigen testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); (3) availability of necessary clinical data; (4) age > 18 years. According to the clinical classification criteria of the "Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (trial the 10th Revised Edition)", the patients were divided into the mild and severe groups. Disease activity in primary Sjögren' s syndrome was assessed using the European League Against Rheumatism (EULAR) Sjögren' s syndrome disease activity index (ESSDAI). Platelet-lymphocyte ratio (PLR), C-reactive protein-lymphocyte ratio (CLR), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and other laboratory data were compared between the two groups within 24-72 hours post-infection. Results: The mild group consisted of 66 cases with an average age of (51. 52±13. 16) years, and the severe group consisted of 14 cases with an average age of (52.64±10.20) years. Disease activity, CRP, platelets, PLR, and CLR were significantly higher in the severe group compared with the mild group (P < 0.05). Univariate analysis using age, disease activity, CRP, platelets, PLR, and CLR as independent variables indicated that disease activity, CRP, PLR, and CLR were correlated with the severity of COVID-19 (P < 0.05). Multivariate logistic regression analysis further confirmed that PLR (OR=1.016, P < 0.05) and CLR (OR=1.504, P < 0.05) were independent risk factors for the severity of COVID-19 in the critically ill patients. Receiver operator characteristic (ROC) curve analysis showed that the area under the curve (AUC) for PLR and CLR was 0.708 (95%CI: 0.588-0.828) and 0.725 (95%CI: 0.578-0.871), respectively. The sensitivity for PLR and CLR was 0.429 and 0.803, respectively, while the highest specificity was 0.714 and 0.758, respectively. The optimal cutoff values for PLR and CLR were 166.214 and 0.870, respectively. Conclusion: PLR and CLR, particularly the latter, may serve as simple and effective indicators for predicting the prognosis of patients with PSS and COVID-19.

Key words: Primary Sjögren's syndrome, Coronavirus disease 2019 (COVID-19), Prognosis, Platelet-lymphocyte ratio, C-reactive protein-lymphocyte ratio

中图分类号:

R593.2

李建斌,吕梦娜,池强,彭一琳,刘鹏程,吴锐. 干燥综合征患者发生重症新型冠状病毒肺炎的早期预测[J]. 北京大学学报（医学版）, 2023, 55(6): 1007-1012.

Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome[J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.

图/表 3

表1

表2

图1

参考文献 41

1	Wiersinga WJ , Rhodes A , Cheng AC , et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): A review[J]. JAMA, 2020, 324 (8): 782- 793. doi: 10.1001/jama.2020.12839
2	Yüce M , Filiztekin E , Özkaya KG . COVID-19 diagnosis: A review of current methods[J]. Biosens Bioelectron, 2021, 172, 112752. doi: 10.1016/j.bios.2020.112752
3	Pablos JL , Galindo M , Carmona L , et al. Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study[J]. Ann Rheum Dis, 2020, 79 (12): 1544- 1549. doi: 10.1136/annrheumdis-2020-218296
4	Luo H , Zhou X . Bioinformatics analysis of potential common pathogenic mechanisms for COVID-19 infection and primary Sjögren’s syndrome[J]. Front Immunol, 2022, 13, 938837. doi: 10.3389/fimmu.2022.938837
5	Brito-Zerón P , Acar-Denizli N , Zeher M , et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8 310 patients: A cross-sectional study from the big data Sjögren project consortium[J]. Ann Rheum Dis, 2017, 76 (6): 1042- 1050. doi: 10.1136/annrheumdis-2016-209952
6	Mariette X , Criswell LA . Primary Sjögren’s syndrome[J]. N Engl J Med, 2018, 378 (10): 931- 939. doi: 10.1056/NEJMcp1702514
7	Zhang G , Hu C , Luo L , et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China[J]. J Clin Virol, 2020, 127, 104364. doi: 10.1016/j.jcv.2020.104364
8	Russell CD , Parajuli A , Gale HJ , et al. The utility of peripheral blood leucocyte ratios as biomarkers in infectious diseases: A systematic review and meta-analysis[J]. J Infect, 2019, 78 (5): 339- 348. doi: 10.1016/j.jinf.2019.02.006
9	Qu R , Ling Y , Zhang YH , et al. Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19[J]. J Med Virol, 2020, 92 (9): 1533- 1541. doi: 10.1002/jmv.25767
10	Lagunas-Rangel FA . Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis[J]. J Med Virol, 2020, 92 (10): 1733- 1734. doi: 10.1002/jmv.25819
11	Shiboski CH , Shiboski SC , Seror R , et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts[J]. Arthritis Rheumatol, 2017, 69 (1): 35- 45. doi: 10.1002/art.39859
12	中华人民共和国国家卫生健康委员会. 新型冠状病毒感染诊疗方案(试行第十版)[J]. 中国合理用药探索, 2023, 20 (1): 1- 11.
13	Seror R , Bowman SJ , Brito-Zeron P , et al. Eular Sjögren' s syndrome disease activity index (ESSDAI): A user guide[J]. RMD Open, 2015, 1 (1): e000022. doi: 10.1136/rmdopen-2014-000022
14	Sacks D , Baxter B , Campbell BCV , et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke: From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO)[J]. J Vasc Interv Radiol, 2018, 29 (4): 441- 453. doi: 10.1016/j.jvir.2017.11.026
15	Del Valle DM , Kim-Schulze S , Huang HH , et al. An inflammatory cytokine signature predicts COVID-19 severity and survival[J]. Nat Med, 2020, 26 (10): 1636- 1643. doi: 10.1038/s41591-020-1051-9
16	Xiang N , Havers F , Chen T , et al. Use of national pneumonia surveillance to describe influenza A(H7N9) virus epidemiology, China, 2004-2013[J]. Emerg Infect Dis, 2013, 19 (11): 1784- 1790.
17	Kaya T , Nalbant A , Kılıçıoǧlu GK , et al. The prognostic signi-ficance of erythrocyte sedimentation rate in COVID-19[J]. Rev Assoc Med Bras (1992), 2021, 67 (9): 1305- 1310. doi: 10.1590/1806-9282.20210618
18	Lapić I , Rogić D , Plebani M . Erythrocyte sedimentation rate is associated with severe coronavirus disease 2019 (COVID-19): A pooled analysis[J]. Clin Chem Lab Med, 2020, 58 (7): 1146- 1148. doi: 10.1515/cclm-2020-0620
19	Roescher N , Tak PP , Illei GG . Cytokines in Sjögren’s syndrome[J]. Oral Dis, 2009, 15 (8): 519- 526. doi: 10.1111/j.1601-0825.2009.01582.x
20	Tahir Huyut M , Huyut Z , lkbahar F , et al. What is the impact and efficacy of routine immunological, biochemical and hemato-logical biomarkers as predictors of COVID-19 mortality[J]. Int Immunopharmacol, 2022, 105, 108542. doi: 10.1016/j.intimp.2022.108542
21	Amgalan A , Othman M . Hemostatic laboratory derangements in COVID-19 with a focus on platelet count[J]. Platelets, 2020, 31 (6): 740- 745. doi: 10.1080/09537104.2020.1768523
22	Tural Onur S , Altın S , Sokucu SN , et al. Could ferritin level be an indicator of COVID-19 disease mortality[J]. J Med Virol, 2021, 93 (3): 1672- 1677. doi: 10.1002/jmv.26543
23	Ardestani A , Azizi Z . Targeting glucose metabolism for treatment of COVID-19[J]. Signal Transduct Target Ther, 2021, 6 (1): 112. doi: 10.1038/s41392-021-00532-4
24	Wang K , Zhang Z , Yu M , et al. 15-day mortality and associated risk factors for hospitalized patients with COVID-19 in Wuhan, China: An ambispective observational cohort study[J]. Intensive Care Med, 2020, 46 (7): 1472- 1474. doi: 10.1007/s00134-020-06047-w
25	Zhang JJ , Cao YY , Tan G , et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients[J]. Allergy, 2021, 76 (2): 533- 550. doi: 10.1111/all.14496
26	Manne BK , Denorme F , Middleton EA , et al. Platelet gene expression and function in patients with COVID-19[J]. Blood, 2020, 136 (11): 1317- 1329. doi: 10.1182/blood.2020007214
27	Pormohammad A , Ghorbani S , Baradaran B , et al. Clinical characteristics, laboratory findings, radiographic signs and outcomes of 61, 742 patients with confirmed COVID-19 infection: A systematic review and meta-analysis[J]. Microb Pathog, 2020, 147, 104390. doi: 10.1016/j.micpath.2020.104390
28	Yang X , Yang Q , Wang Y , et al. Thrombocytopenia and its association with mortality in patients with COVID- 19[J]. J Thromb Haemost, 2020, 18 (6): 1469- 1472. doi: 10.1111/jth.14848
29	Jiang SQ , Huang QF , Xie WM , et al. The association between severe COVID-19 and low platelet count: evidence from 31 observational studies involving 7 613 participants[J]. Br J Haematol, 2020, 190 (1): e29- e33. doi: 10.1111/bjh.16794
30	Xu Z , Shi L , Wang Y , et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome[J]. Lancet Respir Med, 2020, 8 (4): 420- 422. doi: 10.1016/S2213-2600(20)30076-X
31	Shi H , Wang W , Yin J , et al. The inhibition of IL-2/IL-2R gives rise to CD8⁺ T cell and lymphocyte decrease through JAK1-STAT5 in critical patients with COVID-19 pneumonia[J]. Cell Death Dis, 2020, 11 (6): 429. doi: 10.1038/s41419-020-2636-4
32	Liu K , Yang T , Peng XF , et al. A systematic meta-analysis of immune signatures in patients with COVID-19[J]. Rev Med Virol, 2021, 31 (4): e2195. doi: 10.1002/rmv.2195
33	Bohn MK , Lippi G , Horvath A , et al. Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC taskforce evaluation of the latest evidence[J]. Clin Chem Lab Med, 2020, 58 (7): 1037- 1052. doi: 10.1515/cclm-2020-0722
34	Xu H , Zhong L , Deng J , et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa[J]. Int J Oral Sci, 2020, 12 (1): 8. doi: 10.1038/s41368-020-0074-x
35	Gu X , Sha L , Zhang S , et al. Neutrophils and lymphocytes can help distinguish asymptomatic COVID-19 from moderate COVID-19[J]. Front Cell Infect Microbiol, 2021, 11, 654272. doi: 10.3389/fcimb.2021.654272
36	Tan L , Wang Q , Zhang D , et al. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study[J]. Signal Transduct Target Ther, 2020, 5 (1): 33. doi: 10.1038/s41392-020-0148-4
37	Yıldız F , Gökmn O . Haematologic indices and disease activity index in primary Sjögren’s syndrome[J]. Int J Clin Pract, 2021, 75 (3): e13992.
38	Damar Çakırca T , Torun A , Çakırca G , et al. Role of NLR, PLR, ELR and CLR in differentiating COVID-19 patients with and without pneumonia[J]. Int J Clin Pract, 2021, 75 (11): e14781.
39	Sarkar S , Kannan S , Khanna P , et al. Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: A systematic review and meta-analysis[J]. J Med Virol, 2022, 94 (1): 211- 221. doi: 10.1002/jmv.27297
40	Mertoglu C , Huyut MT , Arslan Y , et al. How do routine laboratory tests change in coronavirus disease 2019[J]. Scand J Clin Lab Invest, 2021, 81 (1): 24- 33. doi: 10.1080/00365513.2020.1855470
41	Ben Jemaa A , Salhi N , Ben Othmen M , et al. Evaluation of individual and combined NLR, LMR and CLR ratio for prognosis disease severity and outcomes in patients with COVID-19[J]. Int Immunopharmacol, 2022, 109, 108781. doi: 10.1016/j.intimp.2022.108781

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Parameters	Mild group (n=66)	Severe group (n=14)	t/χ²/Z	P
Age/years, ${\bar x}$±s	51.52±13.16	52.64±10.20	-0.301	0.764
Gender, n(%)			0.653	0.516
Male	2 (3)	0 (0)
Female	64 (97)	14 (100)
Disease activity, n(%)	5 (7)	6 (42.82)	-3.549	0.001
ESR/(mg/L), ${\bar x}$±s	18.42±9.83	17.86±10.29	0.193	8.848
CRP/(μmol/L), M(P₂₅，P₇₅)	0.72 (0.20，1.68)	1.54 (0.54，9.40)	-2.463	0.014
White blood cells/(×10⁹/L), ${\bar x}$±s	5.86±1.95	5.06±1.42	1.447	0.152
Platelets/(×10⁹/L), ${\bar x}$±s	213.42±69.08	253.86±61.02	-2.027	0.046
Monocytes/(×10⁹/L), M(P₂₅，P₇₅)	0.34 (0.28，0.54)	0.34 (0.29，0.56)	-0.120	0.904
Lymphocytes/(×10⁹/L), ${\bar x}$±s	1.79±0.65	1.59±0.41	1.115	0.268
Neutrophils/(×10⁹/L), M(P₂₅，P₇₅)	3.45 (2.32，4.52)	2.94 (2.59，3.98)	-0.684	0.494
Immunoglobulin G/(g/L), ${\bar x}$±s	15.21±4.68	14.32±2.66	0.586	0.560
Immunoglobulin A/(g/L), ${\bar x}$±s	2.79±0.94	2.52±1.27	0.781	0.438
Immunoglobulin M/(g/L), ${\bar x}$±s	1.47±1.06	1.18±0.43	0.857	0.395
Complement C3(g/L), ${\bar x}$±s	0.79±0.12	0.73±0.10	1.309	0.196
Complement C4(g/L), ${\bar x}$±s	0.19±0.05	0.20±0.06	-0.532	0.597
NLR, ${\bar x}$±s	2.38±2.21	2.14±1.15	0.408	0.685
PLR, ${\bar x}$±s	129.95±51.73	163.92±37.90	-2.324	0.023
CLR, M(P₂₅，P₇₅)	0.42 (0.18，0.88)	1.02 (0.37，4.99)	-2.628	0.009
LMR, ${\bar x}$±s	4.75±2.20	4.34±1.52	0.665	0.508
Disease course/years, ${\bar x}$±s	6.96±5.08	9.57±4.03	-1.772	0.081
Medication
Corticosteroids, n(%)	31 (46.97)	8 (57.14)	-0.090	0.928
Methylprednisolone, n(%)	10 (15.15)	3 (21.42)	-0.214	0.831
Hydroxychloroquine, n(%)	24 (36.36)	7 (50)	-0.312	0.755
Cyclosporine, n(%)	3 (4.54)	0 (0)	-0.904	0.366

Parameters	β	SE	Wald	P	OR	95%CI
Disease Activity^a	1.597	0.822	3.775	0.052	4.909	0.986-24.752
CRP^a	0.186	0.102	3.349	0.067	1.205	0.987-1.471
PLR^a，b	0.015	0.007	5.146	0.023	1.016	1.002-1.029
CLR^b	0.408	0.166	5.983	0.014	1.504	1.084-2.085

[1]	张铃福, 陈明, 赵小宇, 王港, 崔龙, 凌晓锋, 王立新, 徐智, 郭丽梅, 侯纯升. 原发灶局限于胆囊壁内胆囊癌大体分型及其与预后和癌前病变的相关性[J]. 北京大学学报（医学版）, 2026, 58(1): 184-189.
[2]	刘源, 石桂秀. 干燥综合征到干燥病的命名变迁[J]. 北京大学学报（医学版）, 2025, 57(6): 1015-1017.
[3]	林文灏, 谢阳, 王芳晴, 王淑盈, 刘香君, 胡凡磊, 贾园. 基于B细胞单细胞转录组测序的干燥综合征分子分型[J]. 北京大学学报（医学版）, 2025, 57(6): 1032-1041.
[4]	向钊, 杨莉, 杨静. 非靶向代谢组学揭示原发性干燥综合征血小板减少患者血清差异代谢物及代谢通路[J]. 北京大学学报（医学版）, 2025, 57(6): 1042-1050.
[5]	赵亚云, 倪梦凡, 李雪, 王蓓, 程功, 何菁, 金月波. 利妥昔单抗治疗原发性干燥综合征肾损害的临床疗效和安全性[J]. 北京大学学报（医学版）, 2025, 57(6): 1051-1060.
[6]	高雅静, 李正芳, 马梦思, 武丽君. SII和SIRI对白塞病葡萄膜炎的风险预测及疾病活动度和预后的评估[J]. 北京大学学报（医学版）, 2025, 57(6): 1067-1073.
[7]	朱丽秀, 陈仁利, 周素娟, 林烨, 汤一榕, 叶桢. 水通道蛋白5对干燥综合征大鼠TLR4/MyD88/NF-κB信号的影响[J]. 北京大学学报（医学版）, 2025, 57(5): 875-883.
[8]	郭博达, 陆敏, 王国良, 张洪宪, 刘磊, 侯小飞, 赵磊, 田晓军, 张树栋. 肾透明细胞癌与非透明细胞癌伴静脉癌栓患者的临床病理特征及预后比较[J]. 北京大学学报（医学版）, 2025, 57(4): 644-649.
[9]	宁圆, 张晓盈, 李雪, 李原, 何菁, 金月波. 干燥综合征并发乳腺淋巴瘤1例[J]. 北京大学学报（医学版）, 2025, 57(4): 808-811.
[10]	李伟浩, 李晶, 张学民, 李伟, 李清乐, 张小明. 术中回收式自体输血对颈动脉体瘤切除术后肿瘤预后的影响[J]. 北京大学学报（医学版）, 2025, 57(2): 272-276.
[11]	毛雅晴, 陈震, 于尧, 章文博, 刘洋, 彭歆. 2型糖尿病对口腔鳞状细胞癌患者预后的影响[J]. 北京大学学报（医学版）, 2024, 56(6): 1089-1096.
[12]	杨玉淑, 齐晅, 丁萌, 王炜, 郭惠芳, 高丽霞. 抗唾液腺蛋白1抗体联合抗腮腺分泌蛋白抗体对干燥综合征的诊断价值[J]. 北京大学学报（医学版）, 2024, 56(5): 845-852.
[13]	欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报（医学版）, 2024, 56(4): 582-588.
[14]	刘帅,刘磊,刘茁,张帆,马潞林,田晓军,侯小飞,王国良,赵磊,张树栋. 伴静脉癌栓的肾上腺皮质癌的临床治疗及预后[J]. 北京大学学报（医学版）, 2024, 56(4): 624-630.
[15]	虞乐,邓绍晖,张帆,颜野,叶剑飞,张树栋. 具有低度恶性潜能的多房囊性肾肿瘤的临床病理特征及预后[J]. 北京大学学报（医学版）, 2024, 56(4): 661-666.